The current landscape of imaging recommendations in cardiovascular clinical guidelines: toward an imaging-guided precision medicine

Antonio Esposito1,2 · Guglielmo Gallone3 · Anna Palmisano1,2 · Livia Marchitelli4 · Federica Catapano4 · Marco Francone4

Abstract
The purpose of this article is to provide an overview on the role of CT scan and MRI according to selected guidelines by the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association (ACC/AHA). ESC and ACC/AHA guidelines were systematically reviewed for recommendations to CT and MRI use in specific cardiovascular (CV) clinical categories. All recommendations were collected in a dataset, including the class of recommendation, the level of evidence (LOE), the specific imaging technique, the clinical purpose of the recommendation and the recommending Society. Among the 43 included guidelines (ESC: n = 18, ACC/AHA: n = 25), 26 (60.4%) contained recommendations for CT scan or MRI (146 recommendations: 62 for CT and 84 for MRI). Class of recommendation IIa (32.9%) was the most represented, followed by I (28.1%), IIb (24%) and III (11.9%). MRI recommendations more frequently being of higher class (I: 36.9%, IIa: 29.8%, IIb: 21.4%, III: 11.9%) as compared to CT (I: 16.1%, IIa: 37.1%, IIb: 27.4%, III: 19.4%). Most of recommendation (55.5%) were based on expert opinion (LOE C). The use of cardiac CT and cardiac MR in the risk assessment, diagnosis, therapeutic and procedural planning is in continuous development, driven by an increasing need to evolve toward an imaging-guided precision medicine, combined with cost-effectiveness and healthcare sustainability. These developments must be accompanied by an increased availability of high-performance scanners in healthcare facilities and should emphasize the need of increasing the number of radiologists fully trained in cardiac imaging.

Keywords AHA/ACC guidelines · ESC guidelines · Cardiovascular magnetic resonance · Cardiac computed tomography angiography

Introduction
Non-invasive cardiovascular imaging with computed tomography (CT) and magnetic resonance imaging (MRI) has become integral part of the clinical routine, following the extraordinary technical evolution of the last 10–15 years. Along with molecular and genomic studies, the recognized importance of cardiac imaging in early disease phenotyping, risk stratification and therapeutic guidance has brought to the development of an imaging-targeted precision medicine, which aims to change paradigms in various cardiological settings.

A crucial step of the process has been the translation of the clinical-radiological evidences into practice guidelines which allow to improve the value (quality and cost-effectiveness) of healthcare [1, 2]. Similarly, use of imaging-based appropriateness criteria has been shown to improve quality, reduce unnecessary imaging and lower healthcare costs [3].
Present article aimed to systematically provide an overview on the role of coronary CT angiography and cardiovascular magnetic resonance (CMR) in selected guidelines provided by the European Society of Cardiology (ESC) and of the American College of Cardiology/American Heart Association (ACC/AHA).

Our purpose would be to emphasize the primary importance of advance imaging in cardiovascular diseases, to promote its increasing utilization by the radiological community and possibly trigger scientific discussion regarding specific multimodality training, competency requirements and reimbursement policies by local governments.

**Guidelines review methods**

To represent the current international landscape of guidance for the use of MRI and CT in cardiovascular medicine, we performed a systematic summary of recommendations regarding the use of imaging in selected guidelines of the ESC and of the ACC/AHA.

All the ESC-ACC/AHA guidelines relating to the following clinical categories were systematically reviewed for recommendations regarding the clinical use of MRI and CT: “Primary prevention,” “Ischemic Heart Disease,” “Valvular disease,” “Heart Failure,” “Pericardial disease,” “Arrhythmias” and “Hypertrophic Cardiomyopathy.” A full list of included guidelines along with the number of recommendations made in each document are reported in Table 1.

All recommendations were collected in a dataset, including the class of recommendation, the level of evidence (LOE) (Table 2), the specific imaging technique, the clinical purpose of the recommendation and the recommending society. A detailed flowchart of the review methodology and classification is reported in Fig. 1.

Only recommendations regarding the imaging of cardiac and coronary structures were included in the present report. As a systematic review of all ESC and ACC/AHA clinical guidelines is beyond the scope of this report, some equally important cardiovascular imaging fields including vascular studies were not included in the search.

When the same recommendation was reported in more than one guideline from the same society, only the most recent was included. When a single recommendation regarded both MRI and CT imaging, it was double counted in order to allow separate analysis for both technologies. Statements regarding the use of CT and MRI imaging in the guideline document without an official specific recommendation were not included in the current analysis but are commented separately. Namely, research was expanded to consensus reports to comprehensively include the most relevant applications without formal recommendation (Paragraph 4).

**The current landscape of clinical cardiovascular guidelines**

Of the 43 included guidelines (ESC: n = 18, ACC/AHA: n = 25), 26 (60.4%) contained recommendations regarding the clinical use of CT or MRI imaging (Table 1). Overall, 146 recommendations (ESC: n = 65, ACC/AHA: n = 81) were made, of which 62 for CT (ESC: n = 28, ACC/AHA: n = 37) and 84 for CMR (ESC: n = 37, ACC/AHA: n = 44) use.

**Class of recommendation**

Overall, the most represented Class of recommendation was IIa (32.9%), followed by I (28.1%), IIb (24%) and III (11.9%). Different patterns were observed between MRI and CT, with MRI recommendations more frequently being of higher class (I: 36.9%, IIa: 29.8%, IIb: 21.4%, III: 11.9%) as compared to CT (I: 16.1%, IIa: 37.1%, IIb: 27.4%, III: 19.4%). Similar patterns were reported between ESC and ACC/AHA guidelines for both CT and MRI recommendations, except for class III MRI recommendations (“Not recommended”) which were more common among ACC/AHA vs. ESC guidelines (17% vs. 2.7%) (Fig. 2).

**Level of evidence**

Regarding the evidence base to support imaging recommendations, most (55.5%) were based on expert opinion (LOE C), while only a small minority (2.1%) was based on evidence derived from adequately powered randomized controlled trials or high-quality meta-analyses (LOE A). This trend was similar for both CT (LOE A: 3.2%, LOE B: 40.3%, LOE C: 56.5%) and MRI (LOE A: 1.2%, LOE B: 44.0%, LOE C: 54.8%) recommendations, in both ESC and ACC/AHA guidelines (Fig. 2).

**Imaging techniques**

Of MRI techniques, contrast-enhanced CMR was the most represented among recommendations (45.8%), followed by stress CMR (39.8%). Among CT techniques, 77.4% recommendations related to contrast-enhanced cardiac/coronary CT angiography, followed by plain CT for the assessment of coronary artery calcium score (19.4%) (Fig. 3).

**Clinical categories**

Ischemic heart disease was the most represented clinical category among recommendations (43.2%), for both MRI (40.5%) and CT (46.8%), with similar patterns between ESC and ACC/AHA guidelines. Of these, 63.6% recommendations referred to the chronic and 36.4% to the acute coronary
syndromes setting. The distribution of recommendations among other clinical indications is detailed in Fig. 4.

Table 1 ESC and ACC/AHA clinical guidelines included in the search, grouped by clinical category

| ESC/ACC/AHA | PMID | No. of rec. | ESC/ACC/AHA | PMID | No. of rec. |
|-------------|------|-------------|-------------|------|-------------|
| **Primary prevention** | | | | | |
| Diabetes, Pre-Diabetes and Cardiovascular Diseases 2019 | 31497854 | 3 | Primary Prevention 2019 | 30879355 | 1 |
| Dyslipidaemias 2019 | 31591002 | 1 | Blood Cholesterol 2018 | 30586774 | 2 |
| Arterial Hypertension 2018 | 30165516 | 0 | High Blood Pressure in Adults 2017 | 29133356 | 0 |
| CVD Prevention in Clinical Practice 2016 | 27222591 | 1 | Assessment of cardiovascular risk 2013 | 24222018 | 1 |
| **Ischemic heart disease** | | | | | |
| Chronic Coronary Syndromes 2019 | 31504439 | 21 | Primary PCI for STEMI (Focused Update) 2015 | 26498666 | 0 |
| Myocardial Revascularization 2018 | 30165437 | 1 | Non-ST-Elevation Acute Coronary Syndromes 2014 | 25249585 | 6 |
| AMI in patients presenting with ST-Segment Elevation 2017 | 28886621 | 4 | Stable Ischemic Heart Disease (focused update) 2014 | 25077860 | 0 |
| ACS in patients presenting without persistent ST-Segment elevation 2015 | 26320110 | 2 | Stable Ischemic Heart Disease 2012 | 23166211 | 30 |
| **Valvular disease** | | | | | |
| Valvular Heart Disease 2017 | 28886619 | 1 | Valvular Heart Disease (Focused Update) 2017 | 28298458 | 2 |
| Infective endocarditis 2015 | 26590409 | 1 | Infective endocarditis 2015 | 26373316 | 0 |
| **Heart failure** | | | | | |
| Acute and Chronic Heart Failure 2016 | 27206819 | 8 | Heart Failure (Focused Update) 2017 | 28461007 | 0 |
| **Arrhythmia** | | | | | |
| Supraventricular Tachycardia 2019 | 31728553 | 0 | Atrial Fibrillation (Focused Update) 2019 | 30703431 | 0 |
| Syncope 2018 | 29562304 | 0 | Bradycardia and Cardiac Conduction Delay 2018 | 30586772 | 7 |
| Atrial Fibrillation 2016 | 27567408 | 0 | Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death 2017 | 29084731 | 7 |
| Ventricular arrhythmias and the prevention of sudden cardiac death 2015 | 26320108 | 4 | Syncope 2017 | 28280231 | 5 |
| Cardiac pacing and cardiac resynchronization therapy 2013 | 23801822 | 0 | Supraventricular Tachycardia 2015 | 26399663 | 0 |
| **Pericardial disease** | | | | | |
| Pericardial diseases 2015 | 26320112 | 7 | Atrial Fibrillation 2014 | 24685669 | 0 |
| Hypertrophic cardiomyopathy | | | | | |
| Hypertrophic Cardiomyopathy 2014 | 25173338 | 11 | Hypertrophic Cardiomyopathy 2011 | 22068434 | 1 |

ESC European Society of Cardiology, ACC American College of Cardiology, AHA American Heart Association

Scope of the recommendation

“Diagnosis” was the most common clinical purpose of imaging recommendations (61.0%), for both CT (61.3%)
and MRI (60.7%), in both ESC and ACC/AHA guidelines. This was followed by “risk stratification” (23.3%), for both CT (24.2%) and MRI (22.6%), in both ESC and ACC/AHA guidelines.

Among all the included documents, a single recommendation from the ESC guidelines for hypertrophic cardiomyopathy was related to preprocedural planning (“CMR with LGE may be considered before septal alcohol ablation or myectomy, to assess the extent and distribution of hypertrophy and myocardial fibrosis”) [4] (Fig. 5).

---

**Table 2** Summary of predefined scales regarding “Classes of Recommendations” and “Level of Evidence” as adopted by the ESC guidelines. Only minor differences exist in the definitions of predefined scales adopted by the ACC/AHA guidelines.

| Classes of recommendations | Levels of evidence |
|----------------------------|-------------------|
| Class I: Evidence that the procedure is clinically useful | Level A: Data from multiple RCTs or meta-analysis |
| Class II: Conflicting evidence that the procedure is clinically useful | Level B: Data from a single RCT or large non-randomized studies |
| Class IIa: Weight of evidence in favor of efficacy | Level C: Expert consensus, data from small non-randomized studies |
| Class IIb: Efficacy less well established | Level D: Expert opinion only |
| Class III: Evidence that the procedure is not clinically useful | Level E: No evidence |

---

**Fig. 1** Guideline review process and classification. We systematically reviewed for recommendations regarding the imaging of cardiac structures, relating to specific clinical categories (cyan boxes). All the recommendations have been divided between the recommending society, and then both ESC and AHA/ACC recommendations have been classified among imaging technique (CT and MRI) and clinical purpose of the recommendation (light green boxes).
Recommendations bottom line: specific settings of clinical use

Primary prevention

Current recommendations in this setting concern
detection of subclinical coronary atherosclerosis and detection of obstructive/ischemia-causing coronary atherosclerosis among at-risk asymptomatic individuals.

Regarding the former goal, coronary artery calcium (CAC) is a highly specific marker of atherosclerotic burden [5], able to improve atherosclerotic cardiovascular disease event prediction among asymptomatic individuals over traditional risk factors [6–9]. The approach of ESC and ACC/AHA guidelines to CAC score diverges, with ESC guidelines expressing weak recommendations for CAC as a risk modifier among low-to-intermediate risk individuals based on clinical assessment (IIb, B). ACC/AHA conversely embraces a broader use of CAC as a potential tool to refine lipid-lowering therapy allocation among patients with uncertain predicted benefit from treatment initiation (IIa, B).

Regarding the detection of obstructive disease among asymptomatic individuals, no recommendations are expressed by ACC/AHA guidelines, while a weak (IIb, B) recommendation for the use of either coronary CT angiography or functional tests (including stress CMR) in patients with diabetes, strong family history or high clinical risk is made by ESC guidelines. The use of coronary CT angiography or functional imaging in patients not fulfilling these requirements is contraindicated (III, C).

**Ischemic heart disease**

In the setting of chronic coronary syndromes (CCS), 2019 ESC guidelines recommend either coronary CT angiography or stress CMR or their combined use to diagnose and to risk stratify obstructive disease among symptomatic patients based on their pre-test disease probability, local expertise and availability, and anticipated quality of the exam (I to IIa, B to C) [10]. Less emphasis on coronary CT angiography use for CCS diagnosis is posed by the outdated 2012 ACC/AHA guidelines, which overall favors functional imaging tests as the exam of choice [11].

Among patients with a prior CCS diagnosis who needs risk assessment (new/worsening symptoms or high clinical prognostic risk), ESC guidelines highlight functional imaging tests as the exam of choice (I, B). Conversely, according to the ACC/AHA guidelines also coronary CT angiography may be considered in this setting (IIa to IIb, B to C). Of note, ACC/AHA guidelines formally contemplate the use of coronary CT angiography for the assessment of patency of bypass grafts or of coronary stents ≥ 3 mm in diameter in patients with new/worsening symptoms (IIb, B); a similar statement is made by ESC guidelines without a formal recommendation.

In the setting of non-ST-segment elevation acute coronary syndromes, ESC guidelines recommend stress imaging to look for inducible ischemia before coronary angiography among patients with suspected low-risk unstable angina (I, A). For both ESC and ACC/AHA guidelines, among patients without prior history of coronary artery disease presenting with chest pain and having an inconclusive diagnostic assessment, coronary CT angiography should be considered as an alternative to coronary angiography (IIa, A) [12, 13].

According to ESC guidelines, among patients with ST-elevation myocardial infarction, stress CMR may be performed following primary percutaneous coronary intervention (PCI) to assess residual ischemia and viability (IIb, C). Furthermore, CMR should be considered when echocardiography is suboptimal, both in-hospital (after primary PCI) and after discharge, for the quantification of left ventricular function (IIa, C) [14]. No recommendations in this setting are provided by the outdated 2013 ACC/AHA guidelines [15].
Valvular disease

Echocardiography plays a leading role in the study of valvular disease, according to both ESC and ACC/AHA guidelines [16, 17].

In this setting, current ACC/AHA guidelines indicate CT and CMR as second-level examination in patients with a poor acoustic window that does not allow the correct evaluation of valve function and/or morphology.

ESC guidelines do not provide a specific class of recommendations for the use of CT and CMR, although their potential clinical value is acknowledged in the documents. Similarly, ESC guidelines on infective endocarditis do not contain formal recommendation for CT or CMR, although CT findings are listed in the modified Duke diagnostic criteria [18]. On the other hand, ACC/AHA guidelines on infective endocarditis suggest the use of CT in patient with suspected valve thrombosis to asses leaflets function and the extent of the thrombus.

Both ESC and ACC/AHA guidelines suggest coronary CT angiography, as alternative to invasive angiography, in order to exclude coronary artery disease (CAD) in low-risk patients candidate to valve surgery (ESC IIa LOE C; ACCF/AHA IIa LOE B) [16, 17].

Heart failure

In the evaluation of heart failure, both ESC and ACC/AHA guidelines suggest the use of CMR in case of inadequate echocardiography findings or suspected infiltrative process and/or when scar burden need to be assessed [19, 20].

CMR has a Class I recommendation (LOE C) to identify myocarditis in patients with new onset or established heart failure according to ESC guidelines [19].

Coronary CT angiography can be used to rule out obstructive CAD in patients with low-to-intermediate pre-test probability and equivocal non-invasive stress tests, as recommended by ESC guidelines, with moderate appropriateness and level of evidence (IIb LOE C) [19].

Arrhythmias

In the widespread setting of cardiac arrhythmias, most of CT and CMR indications, in both ESC and ACC/AHA guidelines, regard ventricular arrhythmias and prevention of sudden cardiac death.

In particular, CT and CMR are recommended in selected patients in whom structural heart disease or myocardial infiltrative processes are suspected [21, 22].

Moreover, ACC/AHA guidelines suggest CT and/or CMR examinations if structural heart disease is suspected, yet not confirmed by other diagnostic modalities, in selected patients with bradycardia or bundle branch block [23] and in suspected cardiac syncope [24].

Pericardial disease

Notably, no dedicated ACC/AHA guidelines are available for pericardial disease. On the other hand, 2015 ESC pericardial disease guidelines strongly recommend CT and/or CMR as second-level testing for diagnostic workup in pericarditis (I LOE C), with a special mention in the diagnosis of constrictive pericarditis (I LOE C). Weaker recommendations are provided for pericardial effusion (IIa LOE C) [25].

Hypertrophic cardiomyopathy

In the workup of patients with known or suspected hypertrophic cardiomyopathy (HCM), both ESC and ACC/AHA guidelines emphasize the role of CMR [4, 20, 26]. In particular, CMR is suggested as diagnostic tool in case of inadequate echocardiographic windows (I LOE B) and to exclude infiltrative processes (ESC IIa LOE B; ACC/AHA IIb LOE C) [4]. In patients with confirmed diagnosis of HCM, CMR can be useful to assess cardiac anatomy, ventricular function, and the extent of myocardial fibrosis, with special mention for evaluation of apical hypertrophy and aneurysm (ESC IIa LOE C; ACC/AHA IIa LOE B) [4].

Moreover, ACC/AHA suggests that CMR can provide additional information in prognostic stratification and/or therapeutic planning [20].

On the other hand, ESC recommends CMR to assess the extent and distribution of hypertrophy and myocardial fibrosis prior to septal alcohol ablation or myectomy (IIb LOE C) and suggests its role as follow-up technique in stable patients (IIb LOE C) [4].

In this scenario, the use of CT angiography is indicated to assess for possible concomitant CAD in low-/intermediate-risk patients according to both ESC and ACC/AHA guidelines (IIa LOE C) and in the diagnosis of HCM, when CMR is contraindicated according to ESC (IIa LOE C) [4, 20].

Statements on clinical use of cardiovascular imaging without formal recommendations

Over the last years, an impressive technological development involved CT and CMR, improving their performances and application fields. This advancement was associated with a relatively recent expansion of the possible clinical applications, including restrictive cardiomyopathy, inflammatory and arrhythmogenic cardiomyopathy and structural intervention. The application of CT and CMR in these settings is still not included in the aforementioned guidelines, but in some cases is part of the clinical routine and is supported
by appropriateness criteria suggested by dedicated expert consensus documents, as reported below.

**Restrictive cardiomyopathy**

According to a recent expert consensus document from European Association of Cardiovascular Imaging (EACVI) and the Working Group on Myocardial and Pericardial diseases of the ESC [27], CMR is recommended for the diagnosis of restrictive cardiomyopathy through an accurate assessment of cardiac chambers volume and mass, beside myocardial tissue characterization.

No formal recommendations have been reported about the use of mapping in this setting, although the clinical experience and the most recent literature suggest that tissue relaxometry imaging, particularly with T1 and T2* mapping, may play a fundamental role in infiltrative cardiomyopathies and iron overload, respectively.

Moreover, when echocardiography is nondiagnostic and CMR contraindicated, CT can be adopted for the evaluation of cardiac chambers volume, myocardial mass, myocardial scar and extracellular volume fraction (ECV) quantification.

**Inflammatory cardiomyopathies**

According to the recent expert consensus document on inflammatory nonischemic cardiomyopathy [28], CMR may be considered as a first-line diagnostic tool for diagnostic workup of acute myocardial inflammation. The use of mapping to detect myocardial inflammation is strongly suggested in this setting, because it has a positive impact on diagnostic accuracy [29] that could be further improved through a mapping-based assessment of myocardial hyperemia [30]. Similarly, CMR may be useful for the identification of various chronic inflammatory conditions, ranging from chronic myocarditis to sarcoidosis to human immunodeficiency virus disease, and to exclude inflammatory substrate of new onset arrhythmias [31]. As previously indicated CMR has a role in identifying myocardial inflammation in patients with new onset or established heart failure [19].

**Arrhythmogenic cardiomyopathy**

According to the recent expert consensus of the EACVI [32], CMR is indicated to support the diagnosis of arrhythmogenic cardiomyopathy together with ECG, histological and functional evaluation, both in the early and advanced disease.

Because of its progressive nature, repeated cardiac imaging is needed to follow disease progression and for risk assessment of life-threatening ventricular arrhythmias.

**Final remarks**

The ESC and AHA/ACC guidelines convey few general remarks:

1. CMR is generally considered appropriate when myocardial tissue characterization (scar, infiltrative disease, inflammation, etc.) is pivotal for the diagnosis; and when echocardiography fails to provide an accurate morpho-functional assessment;

2. Coronary CT angiography gained a central role in the setting of chronic coronary syndrome (i.e., stable angina) according to the recently updated 2019 ESC guidelines. A limited role to the method is conversely conferred by the ACC/AHA guidelines, likely because of the non-up-to-date version of the latest documents (2012–2014).

3. Only a small minority of the recommendations about the use of CT and CMR in the ESC and ACC/AHA guidelines are supported from adequately powered randomized controlled trials or high-quality meta-analyses (LOE A) (Fig. 2). This observation highlights the urgent need of financial supports to large randomized controlled trials, in order to obtain unbiased results supporting the clinical value of cardiac CT and CMR in real clinical world.

Beyond these main messages, several additional considerations could be raised.
The number of class I recommendations is significantly higher for CMR than coronary CT angiography (Fig. 2), likely reflecting the younger age of coronary CT and a more established attitude of cardiologists to use a nonionizing “echocardiography-like” imaging method. This scenario is likely to change in the next future, as a consequence of the development and standardization of new promising CT-derived techniques, such as CT perfusion [36], CT delayed enhancement [37, 38], CT-based extracellular volume quantification [39] and CT-based fractional flow reserve [40].

Although CMR has several formal recommendations in both ESC and ACC/AHA guidelines, the role of parametric mapping techniques is still not established. This could be surprising considering the growing evidences about the positive impact of mapping in the diagnostic and prognostic evaluation of several conditions, as T2* mapping for iron overload, T1 mapping in Fabry disease, ECV in cardiac amyloidosis and parametric mapping in myocarditis [41, 42]. Nevertheless, T2* mapping is currently recommended in disease-specific consensus statement of experts [43], as well as both T1 and T2 mapping technique in expert consensus about the use of CMR in inflammatory myocardial diseases [28]. Despite the Society of Cardiovascular Magnetic Resonance provides clinical recommendation for the use of mapping in this field [44], the inclusion of this technique in the official guidelines of the main cardiological societies is still needed, also with the aim of encouraging a wide technological and cultural upgrading.

Surprisingly, there is a limited consideration for stress CMR as a tool for detecting ischemia in the ACC/AHA guidelines (Fig. 3). This could be shocking, considering that the diagnostic accuracy of stress CMR to detect significant coronary artery disease and to guide revascularization has been proved also by controlled randomized trails [45, 46]. Moreover, the prognostic value and cost-effectiveness of stress CMR were investigated with good results [47]. On the other hand, the ESC guidelines [18] recognize the role of CMR to detect myocardial ischemia, equally to nuclear medicine, but more investments are probably needed in the next future to increase the availability and the technological level of the MR scanners.

Although endovascular or mini-invasive preprocedural planning represent one of the most rapidly evolving application of three-dimensional cardiac imaging techniques, particularly in the settings of structural heart interventions and arrhythmias ablation, formal recommendations provided by the major cardiological society are very limited (Fig. 5), due to the lack of large randomized trial confirming their value. However, several evidences and specific consensus statements have defined CT and CMR as useful tools to support extra-coronary heart interventions [33, 34, 48, 49].

In conclusion, the use of cardiac CT and cardiac MR in the risk assessment, diagnosis, therapeutic and procedural planning is in continuous development, driven by an increasing need to evolve toward an imaging-guided precision medicine, combined with cost-effectiveness and healthcare sustainability. A clear sign of this evolution is the new role recently recognized to the coronary CT angiography in the 2019 ESC Guidelines on Chronic Coronary Syndromes, as recommended initial test for patients with a low to moderate clinical likelihood of disease. However, these developments must be accompanied by an increased availability of high-performance scanners in healthcare facilities and should emphasize the need of increasing the number of radiologists fully trained in cardiac imaging, exploiting and reinforcing different solutions, including the exchanging programs for residents, the education programs of the national and international scientific societies, as well as the dedicated master classes.

Authors’ contributions AE and MF contributed equally to the writing and editing of the final manuscript.

Funding Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement.

Availability of data and material ‘Not applicable’ for that section. Code availability ‘Not applicable’ for that section.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards This article contains data extracted from published papers. All procedures were in accordance with the 1964 Helsinki declaration and its later amendments.

Informed consent This article contains data extracted from published papers. Informed consent was obtained from authors of included papers.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. DiCesare E et al (2013) Clinical indications for the use of cardiac MRI by the SIRM Study Group on Cardiac Imaging. Radiol Med. https://doi.org/10.1007/s11547-012-0899-2
2. De Rubeis G et al (2020) Radiological outpatient’ visits to avoid inappropriate cardiac CT examinations: an 8-year experience report. Radiol Med. https://doi.org/10.1007/s11547-020-01246-3
3. Allen B et al (2017) Summary of the proceedings of the international forum 2016: ‘Imaging referral guidelines and clinical decision support—how can radiologists implement imaging referral guidelines in clinical routine?’ Insights Imaging 1:1. https://doi.org/10.1007/s13244-016-0523-4
4. Zamorano JL et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. https://doi.org/10.1093/eurheartj/ehu284
5. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE (2018) Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2018.05.027
6. Blaha MJ et al (2016) Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA). Circulation. https://doi.org/10.1161/CIRCULATIONAHA.115.018524
7. Budoff MJ et al (2018) Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. https://doi.org/10.1093/eurheartj/ehy217
8. Yano Y et al (2017) Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2017.2498
9. Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J (2019) From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review. J Am Coll Cardiol. 74(12):1608–1617. https://doi.org/10.1016/j.jacc.2019.08.012
10. Task A et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic. pp 407–477. https://doi.org/10.1093/eurheartj/ehz425
11. Fihn SD et al (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary. J Am Coll Cardiol. Immed Past Chair 60(24):164–164. https://doi.org/10.1016/j.jacc.2012.07.012
12. Amsterdam EA et al (2014) 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines, vol 130, no. 25
13. Roffi M et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37(3):267–315. https://doi.org/10.1093/eurheartj/ehz320
14. Ibanez B et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2017:1–66. https://doi.org/10.1093/eurheartj/ehx393
15. O’Gara PT et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2012.11.019
16. Baumgartner H et al (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx391
17. Nishimura RA et al (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary. Circulation. https://doi.org/10.1161/cir.000000000000029
18. Li JS et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infectious endocarditis. Clin Infect Dis. https://doi.org/10.1086/313753
19. Ponikowski P et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. https://doi.org/10.1093/eurheartj/ehw128
20. Yancy CW et al (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2013.05.019
21. Priori SG et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea. Eur Heart J. https://doi.org/10.1093/eurheartj/ehv316
22. Al-Khatib SM et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. https://doi.org/10.1161/CIR.0000000000000549
23. Kusumoto FM et al (2019) 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2018.10.044
24. Shen WK et al (2017) 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American college of cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. https://doi.org/10.1161/CIR.000000000000499
25. Adler Y et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. https://doi.org/10.1093/eurheartj/ehv318
26. Gersh BJ et al (2011) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2011.06.011
27. Habib G et al (2017) Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document In collaboration with the ‘Working Group on myocardial and pericardial diseases’ of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. J Am Heart Cardiovasc Imaging. https://doi.org/10.1016/j.jhjci.2017.03.004
28. Ferreira VM et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2018.09.072
29. Lurz P et al (2016) Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis the MyoRacer-trial. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2016.02.013
30. Palmisano A et al (2020) Early T1 myocardial MRI mapping: value in detecting myocardial hyperemia in acute myocarditis. Radiology. https://doi.org/10.1148/radiol.2020191623
31. Francone M et al (2011) Utility of T2-weighted short-tau inversion recovery (STIR) sequences in cardiac MRI: an overview of clinical applications in ischaemic and non-ischaemic heart disease. Radiol Med. https://doi.org/10.1007/s11547-010-0594-0
32. Haugaa KH et al (2017) Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy—an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jew229
33. Blanke P et al (2019) Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI)/transcatheter
aortic valve replacement (TAVR): an expert consensus document of the society of cardiovascular computed tomography. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2018.12.003

34. Franccone M et al (2020) CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting—a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol. https://doi.org/10.1007/s00330-019-06357-8

35. Leipsic J et al (2019) Core competencies in cardiac CT for imaging structural heart disease interventions: an expert consensus statement. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2019.09.023

36. Nakamura S et al (2020) Prognostic value of stress dynamic computed tomography perfusion with computed tomography delayed enhancement. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2019.12.017

37. Palmisano A, Vignale D, Benedetti G, Del Maschio A, De Cobelli F, Esposito A (2020) Late iodine enhancement cardiac computed tomography for detection of myocardial scars: impact of experience in the clinical practice. Radiol Med. https://doi.org/10.1007/s11547-019-01108-7

38. Esposito A et al (2016) Cardiac CT With Delayed Enhancement in the Characterization of Ventricular Tachycardia Structural Substrate: relationship Between CT-Segmented Scar and Electro-Anatomic Mapping. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2015.10.024

39. Lee HJ et al (2016) Myocardial extracellular volume fraction with dual-energy equilibrium contrast-Enhanced cardiac CT in nonischemic cardiomyopathy: a prospective comparison with cardiac MR imaging. Radiology. https://doi.org/10.1148/radiol.2016151289

40. Patel MR et al (2020) 1-Year impact on medical practice and clinical outcomes of FFRCT: the ADVANCE registry. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2019.03.003

41. Karakas Z et al (2018) Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. Radiol Med. https://doi.org/10.1007/s11547-018-0889-0

42. Tessa C et al (2018) T1 and T2 mapping in the identification of acute myocardial injury in patients with NSTEMI. Radiol Med. https://doi.org/10.1007/s11547-018-0931-2

43. Pennell DJ et al (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American heart association. Circulation. https://doi.org/10.1161/CIR.0b013e31829b2be6

44. Messrokhli DR et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging. J Cardiovasc Magn Reson. https://doi.org/10.1186/s12968-017-0389-8

45. Buckert D, Witzel S, Steinacker JM, Rottbauer W, Bernhardt P (2018) Comparing cardiac magnetic resonance-guided versus angiography-guided treatment of patients with stable coronary artery disease: results from a prospective randomized controlled trial. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2018.05.007

46. Greenwood JP et al (2016) Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2016.12680

47. Kwong RY et al (2019) Cardiac magnetic resonance stress perfusion imaging for evaluation of patients with chest pain. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2019.07.074

48. Cronin EM et al (2020) 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Hear Rhythm. https://doi.org/10.1016/j.hrthm.2019.03.002

49. Mantini C et al (2018) Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography. Radiol Med. https://doi.org/10.1007/s11547-018-0895-2

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.